Jennifer L Hay1, Kate Zielaskowski2, Kirsten Meyer White3, Kimberly Kaphingst4,5, Erika Robers6, Dolores Guest7, Andrew Sussman8, Yvonne Talamantes7, Matthew Schwartz7, Vivian M Rodríguez9, Yuelin Li1, Elizabeth Schofield1, Jessica Bigney10, Keith Hunley11, David Buller12, Marianne Berwick13,14. 1. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Clinical Research Finance, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Division of Epidemiology, Department of Internal Medicine, University of New Mexico, Albuquerque. 4. Department of Communication, University of Utah, Salt Lake City. 5. Huntsman Cancer Institute, University of Utah, Salt Lake City. 6. New Mexico Translation and Transcription, Albuquerque. 7. CRTC Population Sciences Academic Unit, University of New Mexico, Albuquerque. 8. Department of Family and Community Medicine, University of New Mexico, Albuquerque. 9. Center for Mind and Body Health, PLLC, Charlottesville, Virginia. 10. Department of General Internal Medicine, University of New Mexico, Albuquerque. 11. Department of Anthropology, University of New Mexico, Albuquerque. 12. Klein Buendel Inc, Golden, Colorado. 13. Department of Internal Medicine, University of New Mexico, Albuquerque. 14. Department of Dermatology, University of New Mexico, Albuquerque.
Abstract
Importance: Germline variants in the MC1R gene are common and confer moderate melanoma risk in those with varied skin types. Approaches to precision skin cancer prevention that include genetic information may promote risk awareness and risk reduction in the general population, including Hispanics. Objective: To examine prevalence of interest in and uptake of MC1R testing in the general population and examine patterns across demographic and skin cancer risk factors. Design, Setting, and Participants: A randomized clinical trial examined interest in and uptake of MC1R testing among patients at University of New Mexico General Internal Medicine clinics. Study participants were randomized to either a usual-care condition (National Cancer Institute skin cancer pamphlet for diverse skin types) or an MC1R test offer. Participants were registered clinic patients (≥6 months) and English or Spanish fluent. Of the 600 participants recruited to the overall trial, the present study included those 499 participants randomized to theMC1R test offer. Interventions: Participants were presented with the option to log onto the study website to read 3 educational modules presenting the rationale, benefits, and drawbacks of MC1R testing. Main Outcomes and Measures: Main outcomes include website log on (yes vs no), saliva test kit request (yes vs no), and saliva test kit return for MC1R testing (yes vs no). Demographic and skin cancer risk factors were examined as potential predictors of test interest and uptake. Results: Of the 499 participants (220 [44%] non-Hispanic white, 242 [48%] Hispanic, 396 [79%] female; mean [SD] age, 54 [14.3] years), 232 (46%) elected to learn about MC1R testing by logging onto the website; 204 (88%) of those who logged on decided to request testing; and 167 (82%) of those who requested testing returned the kit. The strongest predictors of website log on were race/ethnicity and education (non-Hispanic whites were more likely to log on [odds ratio for Hispanics vs non-Hispanic whites, 0.5; 95% CI, 0.3-0.7], as were more highly educated individuals [odds ratio for more than high school vs high school or less, 2.7; 95% CI, 1.7-4.3]). The strongest predictor of ordering the test was sunburn history (odds ratio, 5.4; 95% CI, 2.3-12.9 vs no sunburn history). Conclusions and Relevance: There were moderately high levels of MC1R test interest and uptake in this diverse sample. Addressing potential barriers to testing may be warranted as genomic information becomes integrated into general population approaches to the precision prevention of skin cancer. Trial Registration: ClinicalTrials.gov identifier: NCT03130569.
RCT Entities:
Importance: Germline variants in the MC1R gene are common and confer moderate melanoma risk in those with varied skin types. Approaches to precision skin cancer prevention that include genetic information may promote risk awareness and risk reduction in the general population, including Hispanics. Objective: To examine prevalence of interest in and uptake of MC1R testing in the general population and examine patterns across demographic and skin cancer risk factors. Design, Setting, and Participants: A randomized clinical trial examined interest in and uptake of MC1R testing among patients at University of New Mexico General Internal Medicine clinics. Study participants were randomized to either a usual-care condition (National Cancer Institute skin cancer pamphlet for diverse skin types) or an MC1R test offer. Participants were registered clinic patients (≥6 months) and English or Spanish fluent. Of the 600 participants recruited to the overall trial, the present study included those 499 participants randomized to the MC1R test offer. Interventions: Participants were presented with the option to log onto the study website to read 3 educational modules presenting the rationale, benefits, and drawbacks of MC1R testing. Main Outcomes and Measures: Main outcomes include website log on (yes vs no), saliva test kit request (yes vs no), and saliva test kit return for MC1R testing (yes vs no). Demographic and skin cancer risk factors were examined as potential predictors of test interest and uptake. Results: Of the 499 participants (220 [44%] non-Hispanic white, 242 [48%] Hispanic, 396 [79%] female; mean [SD] age, 54 [14.3] years), 232 (46%) elected to learn about MC1R testing by logging onto the website; 204 (88%) of those who logged on decided to request testing; and 167 (82%) of those who requested testing returned the kit. The strongest predictors of website log on were race/ethnicity and education (non-Hispanic whites were more likely to log on [odds ratio for Hispanics vs non-Hispanic whites, 0.5; 95% CI, 0.3-0.7], as were more highly educated individuals [odds ratio for more than high school vs high school or less, 2.7; 95% CI, 1.7-4.3]). The strongest predictor of ordering the test was sunburn history (odds ratio, 5.4; 95% CI, 2.3-12.9 vs no sunburn history). Conclusions and Relevance: There were moderately high levels of MC1R test interest and uptake in this diverse sample. Addressing potential barriers to testing may be warranted as genomic information becomes integrated into general population approaches to the precision prevention of skin cancer. Trial Registration: ClinicalTrials.gov identifier: NCT03130569.
Authors: Lisa G Aspinwall; Tammy K Stump; Jennifer M Taber; Danielle M Drummond; Wendy Kohlmann; Marjan Champine; Sancy A Leachman Journal: Transl Behav Med Date: 2018-01-29 Impact factor: 3.046
Authors: Elliot J Coups; Jerod L Stapleton; Sharon L Manne; Shawna V Hudson; Amanda Medina-Forrester; Stephen A Rosenberg; Marsha Gordon; Kristina S Tatum; June K Robinson; Ana Natale-Pereira; James S Goydos Journal: J Behav Med Date: 2014-02-15
Authors: Colleen M McBride; Sharon Hensley Alford; Robert J Reid; Eric B Larson; Andreas D Baxevanis; Lawrence C Brody Journal: Genet Med Date: 2009-08 Impact factor: 8.822
Authors: Devarati Mitra; Xi Luo; Ann Morgan; Jin Wang; Mai P Hoang; Jennifer Lo; Candace R Guerrero; Jochen K Lennerz; Martin C Mihm; Jennifer A Wargo; Kathleen C Robinson; Suprabha P Devi; Jillian C Vanover; John A D'Orazio; Martin McMahon; Marcus W Bosenberg; Kevin M Haigis; Daniel A Haber; Yinsheng Wang; David E Fisher Journal: Nature Date: 2012-10-31 Impact factor: 49.962
Authors: Elena Pasquali; José C García-Borrón; Maria Concetta Fargnoli; Sara Gandini; Patrick Maisonneuve; Vincenzo Bagnardi; Claudia Specchia; Fan Liu; Manfred Kayser; Tamar Nijsten; Eduardo Nagore; Rajiv Kumar; Johan Hansson; Peter A Kanetsky; Paola Ghiorzo; Tadeusz Debniak; Wojciech Branicki; Nelleke A Gruis; Jiali Han; Terry Dwyer; Leigh Blizzard; Maria Teresa Landi; Giuseppe Palmieri; Gloria Ribas; Alexander Stratigos; M Laurin Council; Philippe Autier; Julian Little; Julia Newton-Bishop; Francesco Sera; Sara Raimondi Journal: Int J Cancer Date: 2014-06-18 Impact factor: 7.396
Authors: Kirsten A M White; Yvonne T Dailey; Dolores D Guest; Kate Zielaskowski; Erika Robers; Andrew Sussman; Keith Hunley; Christopher R Hughes; Matthew R Schwartz; Kimberly A Kaphingst; David B Buller; Jennifer L Hay; Marianne Berwick Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-09-05 Impact factor: 4.254
Authors: Erva Khan; Kimberly A Kaphingst; Kirsten Meyer White; Andrew Sussman; Dolores Guest; Elizabeth Schofield; Yvonne T Dailey; Erika Robers; Matthew R Schwartz; Yuelin Li; David Buller; Keith Hunley; Marianne Berwick; Jennifer L Hay Journal: J Community Genet Date: 2021-11-19
Authors: Kristen E Riley; Andrew L Sussman; Elizabeth Schofield; Dolores D Guest; Yvonne T Dailey; Matthew R Schwartz; David B Buller; Keith Hunley; Kimberly A Kaphingst; Marianne Berwick; Jennifer L Hay Journal: Med Decis Making Date: 2021-08-28 Impact factor: 2.583
Authors: Emily C Shen; Swetha Srinivasan; Lauren E Passero; Caitlin G Allen; Madison Dixon; Kimberly Foss; Brianna Halliburton; Laura V Milko; Amelia K Smit; Rebecca Carlson; Megan C Roberts Journal: Front Genet Date: 2022-07-04 Impact factor: 4.772
Authors: Smita C Banerjee; Andrew Sussman; Elizabeth Schofield; Dolores D Guest; Yvonne S Dailey; Matthew R Schwartz; David B Buller; Keith Hunley; Kimberly A Kaphingst; Marianne Berwick; Jennifer L Hay Journal: J Health Commun Date: 2021-10-06
Authors: Jennifer M Taber; Lisa G Aspinwall; Danielle M Drummond; Tammy K Stump; Wendy Kohlmann; Marjan Champine; Pamela Cassidy; Sancy A Leachman Journal: Ann Behav Med Date: 2021-02-12
Authors: Jennifer L Hay; Kimberly A Kaphingst; David Buller; Elizabeth Schofield; Kirsten Meyer White; Andrew Sussman; Dolores Guest; Yvonne T Dailey; Erika Robers; Matthew R Schwartz; Yuelin Li; Keith Hunley; Marianne Berwick Journal: Cancers (Basel) Date: 2021-08-12 Impact factor: 6.639
Authors: Kimberly A Kaphingst; Erva Khan; Kirsten Meyer White; Andrew Sussman; Dolores Guest; Elizabeth Schofield; Yvonne T Dailey; Erika Robers; Matthew R Schwartz; Yuelin Li; David Buller; Keith Hunley; Marianne Berwick; Jennifer L Hay Journal: Patient Educ Couns Date: 2020-08-01